Quest Diagnostics Incorporated (NYSE:DGX) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 3.02 by 16 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys. 13 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell. A sell rating was given by 1 analyst.
Other Equity analysts have also commented on the company shares. Credit Suisse initiates coverage on Quest Diagnostics Incorporated (NYSE:DGX) The current rating of the shares is Neutral. Equity Analysts at the Firm announces the price target to $72 per share. The rating by the firm was issued on March 15, 2016.
Quest Diagnostics Incorporated (NYSE:DGX): The mean estimate for the short term price target for Quest Diagnostics Incorporated (NYSE:DGX) stands at $75.42 according to 12 Analysts. The higher price target estimate for the stock has been calculated at $84 while the lower price target estimate is at $70.
Quest Diagnostics Incorporated (NYSE:DGX) rose 0.04% or 0.03 points on Tuesday and made its way into the gainers of the day. After trading began at $78.18 the stock was seen hitting $78.215 as a peak level and $77.35 as the lowest level. The stock ended up at $77.87. The daily volume was measured at 884,206 shares. The 52-week high of the share price is $78.97 and the 52-week low is $59.655. The company has a market cap of $11,015 million.
Shares of Quest Diagnostics Inc. rose by 0.58% in the last five trading days and 1.76% for the last 4 weeks. Quest Diagnostics Inc. is up 12.05% in the last 3-month period. Year-to-Date the stock performance stands at 10.68%.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.